Retigabine dose-optimization adjunctive treatment study in adults with partial-onset seizures

Phase 4, randomised, double-blind trial in epilepsy and Focal Onset Epilepsy comparing Trobalt adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Percent change in 28-day total partial-onset seizure frequency from baseline to double-blind phase. Started Dec 2012; status: terminated.